First Trust Advisors LP bought a new position in Crispr Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,085 shares of the company’s stock, valued at approximately $987,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. BSW Wealth Partners bought a new stake in Crispr Therapeutics in the second quarter valued at approximately $39,000. Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter valued at approximately $5,165,000. BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics in the second quarter valued at approximately $41,000. Bank of New York Mellon Corp lifted its position in Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after purchasing an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC lifted its position in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. 49.82% of the stock is owned by institutional investors and hedge funds.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last ninety days. 21.40% of the stock is currently owned by insiders.
NASDAQ CRSP opened at $66.33 on Tuesday. Crispr Therapeutics AG has a 12 month low of $22.22 and a 12 month high of $74.00. The stock has a market cap of $3.61 billion, a P/E ratio of -19.28 and a beta of 3.30. The stock’s fifty day moving average price is $60.48 and its 200-day moving average price is $48.87. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. As a group, analysts forecast that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
Several analysts have weighed in on CRSP shares. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Finally, TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $69.54.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: The role of implied volatility with call option volume
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.